值得注意的是，东阳光长江药业即将与广东东阳光药业完成一体化合并，成为一家集研产销于一体的综合性制药公司。分析人士表示，未来一体化完成后，其专注适应症领域全球市场规模有望超千亿，依托强大研产销体系，公司有望成为千亿市值规模医药龙头企业。Guangdong HEC Technology Holding (01558) rose more than 4% against the trend. As of the release, it rose 3.33% to HKD 9.32 with a turnover of HKD 11.2045 million.
According to the Zhitongcaijing APP, Guangdong HEC Technology Holding (01558) rose more than 4% against the trend. As of the release, it rose 3.33% to HKD 9.32 with a turnover of HKD 11.2045 million.
CITIC SEC stated that the Hang Seng Composite Index will undergo a new review on August 16th and this adjustment will officially take effect on September 9th, and the Hong Kong Stock Connect will correspondingly adjust. The bank predicts that there will be 19 symbols eligible for the Hong Kong Stock Connect, including Guangdong HEC Technology Holding. Analysts say that after entering the Hong Kong Stock Connect, the company is expected to attract southbound capital with its steady fundamentals and relatively low valuations, and a new round of valuation leap may occur.
It is worth noting that Guangdong HEC Technology Holding is about to complete the integration with Guangdong HEC Technology Pharmaceutical Industry Co., Ltd., becoming a comprehensive pharmaceutical company integrating research, production, and sales. Analysts say that after the integration is completed, the company's focus on the global market size of the indications may exceed 100 billion yuan. With a strong research, production and sales system, the company is expected to become a leading pharmaceutical company with a market cap of over 100 billion yuan.